A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients (HTLP Necker)

  • End date
    Jun 3, 2025
  • participants needed
  • sponsor
    Assistance Publique - Hôpitaux de Paris
Updated on 14 October 2022


The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients.


Not provided

Condition Pediatric Patients, Any Type of Severe Combined Immunodeficiency (SCID), Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Treatment Human T Lymphoid Progenitor (HTLP) injection
Clinical Study IdentifierNCT03879876
SponsorAssistance Publique - Hôpitaux de Paris
Last Modified on14 October 2022


Yes No Not Sure

Inclusion Criteria

Pediatric patients affected by any type of SCID confirmed by clinical, immunological and/or molecular diagnosis and eligible for an allogeneic HSCT
Absence of a matched sibling donor or a matched unrelated donor (MUD) 10/10
Clinical conditions incompatible with the search of a MUD
Written, informed consent of parents/ legal representative (child)
Age ≤ 2 years at the time of screening
No prior therapy with allogeneic stem cell transplantation
No treatment with another investigational drug within one month before inclusion
Patient affiliated to social security

Exclusion Criteria

Presence of an HLA genoidentical donor
Absence of written parental consent
Treatment with another investigational drug within one month before inclusion
Positive for HIV infection by genome PCR
Contra-indication to allogeneic transplantation or conditioning therapy (except SCID patients with DNA repair deficiency)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note